000136755 001__ 136755
000136755 005__ 20240229105057.0
000136755 0247_ $$2doi$$a10.3390/v10060302
000136755 0247_ $$2pmid$$apmid:29865280
000136755 0247_ $$2pmc$$apmc:PMC6024310
000136755 037__ $$aDKFZ-2018-01193
000136755 041__ $$aeng
000136755 082__ $$a610
000136755 1001_ $$0P:(DE-He78)9c8a10405c0a6ffe7941d65e89cb7c61$$aLacroix, Jeannine Ariane Desiree$$b0$$eFirst author$$udkfz
000136755 245__ $$aPreclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
000136755 260__ $$aBasel$$bMDPI$$c2018
000136755 3367_ $$2DRIVER$$aarticle
000136755 3367_ $$2DataCite$$aOutput Types/Journal article
000136755 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536312878_14253
000136755 3367_ $$2BibTeX$$aARTICLE
000136755 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136755 3367_ $$00$$2EndNote$$aJournal Article
000136755 520__ $$aAbout 70% of all Ewing sarcoma (EWS) patients are diagnosed under the age of 20 years. Over the last decades little progress has been made towards finding effective treatment approaches for primarily metastasized or refractory Ewing sarcoma in young patients. Here, in the context of the search for novel therapeutic options, the potential of oncolytic protoparvovirus H-1 (H-1PV) to treat Ewing sarcoma was evaluated, its safety having been proven previously tested in adult cancer patients and its oncolytic efficacy demonstrated on osteosarcoma cell cultures. The effects of viral infection were tested in vitro on four human Ewing sarcoma cell lines. Notably evaluated were effects of the virus on the cell cycle and its replication efficiency. Within 24 h after infection, the synthesis of viral proteins was induced. Efficient H-1PV replication was confirmed in all four Ewing sarcoma cell lines. The cytotoxicity of the virus was determined on the basis of cytopathic effects, cell viability, and cell lysis. These in vitro experiments revealed efficient killing of Ewing sarcoma cells by H-1PV at a multiplicity of infection between 0.1 and 5 plaque forming units (PFU)/cell. In two of the four tested cell lines, significant induction of apoptosis by H-1PV was observed. H-1PV thus meets all the in vitro criteria for a virus to be oncolytic towards Ewing sarcoma. In the first xenograft experiments, however, although an antiproliferative effect of intratumoral H-1PV injection was observed, no significant improvement of animal survival was noted. Future projects aiming to validate parvovirotherapy for the treatment of pediatric Ewing sarcoma should focus on combinatorial treatments and will require the use of patient-derived xenografts and immunocompetent syngeneic animal models.
000136755 536__ $$0G:(DE-HGF)POF3-316$$a316 - Infections and cancer (POF3-316)$$cPOF3-316$$fPOF III$$x0
000136755 588__ $$aDataset connected to CrossRef, PubMed,
000136755 7001_ $$00000-0002-6598-8369$$aKis, Zoltán$$b1
000136755 7001_ $$0P:(DE-HGF)0$$aJosupeit, Rafael$$b2
000136755 7001_ $$0P:(DE-He78)22e6128f8d5789c3a0c86bb0e5ca54e5$$aSchlund, Franziska$$b3$$udkfz
000136755 7001_ $$0P:(DE-He78)680b50042d6f35e6482a0c32a0913a56$$aStroh-Dege, Alexandra$$b4$$udkfz
000136755 7001_ $$0P:(DE-He78)fe22d4e4d95a683330aff285cd686b18$$aFrank-Stöhr, Monika$$b5$$udkfz
000136755 7001_ $$0P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f$$aLeuchs, Barbara$$b6$$udkfz
000136755 7001_ $$0P:(DE-HGF)0$$aSchlehofer, Jörg R$$b7
000136755 7001_ $$0P:(DE-He78)2d7958ea507b0b738619074b38ec6d54$$aRommelaere, Jean$$b8$$udkfz
000136755 7001_ $$0P:(DE-He78)349f3daee0a618de13d40851744cf00c$$aDinsart, Christiane$$b9$$eLast author$$udkfz
000136755 773__ $$0PERI:(DE-600)2516098-9$$a10.3390/v10060302$$gVol. 10, no. 6, p. 302 -$$n6$$p302 $$tViruses$$v10$$x1999-4915$$y2018
000136755 909CO $$ooai:inrepo02.dkfz.de:136755$$pVDB
000136755 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9c8a10405c0a6ffe7941d65e89cb7c61$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136755 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-6598-8369$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136755 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136755 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)22e6128f8d5789c3a0c86bb0e5ca54e5$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000136755 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)680b50042d6f35e6482a0c32a0913a56$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000136755 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fe22d4e4d95a683330aff285cd686b18$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000136755 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000136755 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000136755 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d7958ea507b0b738619074b38ec6d54$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000136755 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)349f3daee0a618de13d40851744cf00c$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000136755 9131_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000136755 9141_ $$y2018
000136755 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bVIRUSES-BASEL : 2015
000136755 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136755 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136755 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136755 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000136755 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000136755 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000136755 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136755 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136755 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136755 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136755 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136755 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136755 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136755 9201_ $$0I:(DE-He78)F010-20160331$$kF010$$lTumorvirologie$$x0
000136755 9201_ $$0I:(DE-He78)F170-20160331$$kF170$$lVirus-assoziierte Karzinogenese$$x1
000136755 980__ $$ajournal
000136755 980__ $$aVDB
000136755 980__ $$aI:(DE-He78)F010-20160331
000136755 980__ $$aI:(DE-He78)F170-20160331
000136755 980__ $$aUNRESTRICTED